<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691132</url>
  </required_header>
  <id_info>
    <org_study_id>2007NT127</org_study_id>
    <secondary_id>R01CA122244</secondary_id>
    <secondary_id>0712M22651</secondary_id>
    <nct_id>NCT00691132</nct_id>
  </id_info>
  <brief_title>Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers</brief_title>
  <official_title>Randomized Trial of PEITC as a Modifier of NNK Metabolism in Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use
      of phenethyl isothiocyanate may prevent lung cancer in people who smoke cigarettes.

      PURPOSE: This randomized clinical trial is studying phenethyl isothiocyanate to see how well
      it works in preventing lung cancer in smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine whether oral phenethyl isothiocyanate (PEITC) affects urinary levels of
           biomarkers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in current
           smokers.

      Secondary

        -  To determine the effect of GSTM1 genotype on PEITC's impact on urinary biomarkers of NNK
           metabolism.

        -  To determine the effect of GSTM1 genotype on the metabolism and excretion of PEITC as
           measured by urinary levels of its major metabolite.

        -  To determine whether oral PEITC affects molecular markers of cell proliferation (Ki-67)
           and apoptosis (caspase-3 and TUNEL) in bronchial tissue.

      OUTLINE: Patients are stratified according to GST genotypes (GSTM1 null-null genotype vs
      GSTM1-positive genotype). All participants are initially enrolled in the short-term trial.
      After the completion of the short-term trial, only those participants meeting certain
      criteria may proceed to the long-term trial.

        -  Short-term trial: Participants are randomized to 1 of 2 treatment arms.

             -  Arm I: Participants are asked to smoke only deuterated NNK cigarettes (provided by
                the study) and record the exact number of cigarettes smoked and alcoholic drinks
                consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate
                (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for
                5 days in week 4. Participants keep a diary of all food and beverages consumed on
                the days that PEITC or placebo are taken.

             -  Arm II: Participants receive oral placebo four times daily for 5 days in week 2 and
                oral PEITC four times daily for 5 days in week 4. Participants are also asked to
                smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and
                alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.

      After completion of the short-term trial, participants undergo a wash-out period for 1 month
      in which they are asked to resume smoking regular cigarettes. Participants are offered
      smoking cessation assistance, if desired. Only those participants meeting certain criteria
      may proceed to the long-term trial after the 1-month wash-out period.

        -  Long-term trial: Participants are randomized to 1 of 2 treatment arms.

             -  Arm I: Participants receive oral PEITC twice daily for 12 months.

             -  Arm II: Participants receive oral placebo twice daily for 12 months. Participants
                in both arms complete a 3-day food diary monthly for 12 months and a food-frequency
                questionnaire at baseline and at the completion of study treatment.

      All participants undergo blood and urine sample collection periodically for laboratory
      studies. Participants enrolled in the long-term trial also undergo bronchoscopy and tissue
      biopsy at baseline and at the completion study treatment. Urine samples are examined by
      liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) for
      various biomarkers. Tissue samples are examined by IHC for Ki-67, TUNEL, and caspase-3
      expression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Levels of Biomarkers of NNK Metabolism</measure>
    <time_frame>2 periods, 5 days each on PEITC or Placebo, with washout week between</time_frame>
    <description>Urinary levels of Total ITC and PEITC-NAC by treatment sequence groups and treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Levels of Biomarkers of NNK Metabolism</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>The ratio of urinary [pyridine-D4]hydroxy acid : total [pyridine-D4]NNAL will be measured. This ratio is not expected to be influenced by the number of cigarettes smoked per day, or smoking topography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of GSTM1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</measure>
    <time_frame>After 5 days of PEITC treatment</time_frame>
    <description>Measured by high-performance liquid chromatography (HPLC). The aim is to determine the possible differential effects of GSTM1 genotype on PEITC excretion, using the method of Chung et al. The method will result in quantitative recovery of the PEITC-NAC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of GSTT1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>Measured by high-performance liquid chromatography (HPLC). The aim is to determine the possible differential effects of GSTT1 genotype on PEITC excretion, using the method of Chung et al. The method will result in quantitative recovery of the PEITC-NAC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Effects of GSTM1 and GSTT1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</measure>
    <time_frame>After 5 days of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Levels of [Pyridine-D4]Hydroxy Acid:Total [Pyridine-D4]NNAL Ratio by GSTM1 and GSTT1 Genotype.</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>% Difference in ratio of urinary [pyridine-D4]hydroxy acid : total [pyridine-D4]NNAL while on PEITC compared to while on Placebo ((PEITC - Placebo) / PEITC) x 100%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>PEITC - Placebo (short-term trial)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - PEITC (short-term trial)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenethyl isothiocyanate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>PEITC - Placebo (short-term trial)</arm_group_label>
    <arm_group_label>Placebo - PEITC (short-term trial)</arm_group_label>
    <other_name>PEITC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>PEITC - Placebo (short-term trial)</arm_group_label>
    <arm_group_label>Placebo - PEITC (short-term trial)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Initial from phone interview:

          -  Currently smoking 10-45 cigarettes per day for the past year;

          -  Between the ages of 21 and 70 years;

          -  In apparently good physical health with no unstable medical conditions including
             seizures or cancer;

          -  In stable and good mental health, i.e., currently do not experience unstable or
             untreated psychiatric diagnosis, including substance abuse, as determined by the
             DSM-IV criteria, during the past six months;

          -  Not using any other tobacco or nicotine-containing products;

          -  Not on methadone maintenance or stimulants such as ephedra; not a regular user of
             street drugs and if uses occasionally, willing to abstain during the study; not taking
             any drugs known to be P4501A6 substrates such as phenobarbital, rifampicin,
             dexamethasone, ketoconazole, methoxsalen, pilocarpine, or tranylcypromine due to their
             role in NNK metabolism;

          -  Does not average more than 21 alcoholic drinks per week;

          -  Willing to perform study activities such as having blood sample drawn, urine
             collection, multiple clinic visits;

          -  For female subjects of child bearing potential, not known to be pregnant or nursing,
             or planning to become pregnant within next 12 months.

        For enrollment in the Short-Term Trial:

          -  Subjects who are generally healthy with liver enzyme and blood count values within the
             ranges shown below based on blood samples drawn at the second screening visit.
             Specifically:

               -  White blood cells ≥ 3,000/mL

               -  Total bilirubin ≤ 1.5 x upper limits of normal (ULN)

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN

               -  BUN and serum creatinine ≤ 1.5 x ULN

        For enrollment in the Long-Term Trial:

          -  Participated in the short-term trial and invited to participate in the long-term
             trial;

          -  Possess the GSTM1 null-null genotype;

          -  Smoke 20 or more cigarettes/day with a cumulative smoking history of 20 or more
             pack-years (one pack-year equals to smoking a pack of cigarettes a day for one year);

          -  Normal liver enzymes based on blood sample drawn during 1 month wash-out;

          -  Determined to be a good candidate for the bronchoscopy procedure by a primary care
             physician.

        Exclusion Criteria:

          -  Subjects with uncontrolled hypertension, uncontrolled diabetes mellitus, unstable
             coronary artery disease, history of cancer other than non-melanoma skin cancer, and
             pregnant or lactating women will not be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothy K. Hatsukami, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yuan JM, Stepanov I, Murphy SE, Wang R, Allen S, Jensen J, Strayer L, Adams-Haduch J, Upadhyaya P, Le C, Kurzer MS, Nelson HH, Yu MC, Hatsukami D, Hecht SS. Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. Cancer Prev Res (Phila). 2016 May;9(5):396-405. doi: 10.1158/1940-6207.CAPR-15-0380. Epub 2016 Mar 7.</citation>
    <PMID>26951845</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <results_first_submitted>February 14, 2017</results_first_submitted>
  <results_first_submitted_qc>February 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>tobacco use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenethyl isothiocyanate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEITC - Placebo (Short-term Trial)</title>
          <description>Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
phenethyl isothiocyanate: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="P2">
          <title>Placebo - PEITC (Short-term Trial)</title>
          <description>Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
phenethyl isothiocyanate: Given orally
placebo: Given orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="54">107 total randomized. Approximately 1/2 per arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41">45 completed, but 4 excluded b/c urinary measures indicated they did not smoke study cigarettes.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEITC - Placebo (Short-term Trial)</title>
          <description>Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
phenethyl isothiocyanate: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Placebo - PEITC (Short-term Trial)</title>
          <description>Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
phenethyl isothiocyanate: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="10.6"/>
                    <measurement group_id="B2" value="41.1" spread="9.6"/>
                    <measurement group_id="B3" value="41.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="4.8"/>
                    <measurement group_id="B2" value="28.0" spread="6.3"/>
                    <measurement group_id="B3" value="28.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Level of Education</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>High school or lower</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoking rate</title>
          <units>cigarettes/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.3" spread="6.6"/>
                    <measurement group_id="B2" value="19.0" spread="6.7"/>
                    <measurement group_id="B3" value="19.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarette smoking history</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years of smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="10.3"/>
                    <measurement group_id="B2" value="17.9" spread="9.4"/>
                    <measurement group_id="B3" value="16.3" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age at starting smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="4.9"/>
                    <measurement group_id="B2" value="15.1" spread="4.6"/>
                    <measurement group_id="B3" value="15.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age became regular smokers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.6" spread="7.1"/>
                    <measurement group_id="B2" value="17.7" spread="5.2"/>
                    <measurement group_id="B3" value="18.1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol drinking</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monthly or less</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than monthly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GSTM1 &amp; GSTT1 genotypes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Both present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present/null</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Null/present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both null</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Levels of Biomarkers of NNK Metabolism</title>
        <description>Urinary levels of Total ITC and PEITC-NAC by treatment sequence groups and treatment period.</description>
        <time_frame>2 periods, 5 days each on PEITC or Placebo, with washout week between</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PEITC-Placebo</title>
            <description>Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in Period 1 and oral placebo four times daily for 5 days in Period 2, with washout period in between. Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - PEITC</title>
            <description>Participants receive oral placebo four times daily for 5 days in Period 1 and oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in Period 2, with washout period in between. Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Levels of Biomarkers of NNK Metabolism</title>
          <description>Urinary levels of Total ITC and PEITC-NAC by treatment sequence groups and treatment period.</description>
          <units>pmol/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Period 1 - Total ITC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" lower_limit="37.4" upper_limit="48.9"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.19" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2 - Total ITC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="0.13" upper_limit="0.46"/>
                    <measurement group_id="O2" value="49.7" lower_limit="43.2" upper_limit="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 1 - PEITC-NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7" lower_limit="46.3" upper_limit="69.3"/>
                    <measurement group_id="O2" value="0.27" lower_limit="0.08" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period 2 - PEITC-NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.01" upper_limit="0.85"/>
                    <measurement group_id="O2" value="68.1" lower_limit="56.6" upper_limit="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinary Levels of Biomarkers of NNK Metabolism</title>
        <description>The ratio of urinary [pyridine-D4]hydroxy acid : total [pyridine-D4]NNAL will be measured. This ratio is not expected to be influenced by the number of cigarettes smoked per day, or smoking topography.</description>
        <time_frame>After 5 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants receive oral placebo four times daily for 5 days in either Period 1 or Period 2.</description>
          </group>
          <group group_id="O2">
            <title>PEITC</title>
            <description>Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in either Period 1 or Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Levels of Biomarkers of NNK Metabolism</title>
          <description>The ratio of urinary [pyridine-D4]hydroxy acid : total [pyridine-D4]NNAL will be measured. This ratio is not expected to be influenced by the number of cigarettes smoked per day, or smoking topography.</description>
          <units>pmol/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total [pyridine-D4]NNAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.366" lower_limit="0.286" upper_limit="0.396"/>
                    <measurement group_id="O2" value="0.366" lower_limit="0.285" upper_limit="0.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[pyridine-D4]Hydroxy acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" lower_limit="0.128" upper_limit="0.175"/>
                    <measurement group_id="O2" value="0.140" lower_limit="0.120" upper_limit="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>[pyridine-D4]Hydroxy acid :[pyridine-D4]total NNAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.455" lower_limit="0.409" upper_limit="0.508"/>
                    <measurement group_id="O2" value="0.420" lower_limit="0.377" upper_limit="0.469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>% difference between Placebo and PEITC periods in the ratio of [pyridine-D4]Hydroxy acid : [pyridine-D4] total NNAL</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of GSTM1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</title>
        <description>Measured by high-performance liquid chromatography (HPLC). The aim is to determine the possible differential effects of GSTM1 genotype on PEITC excretion, using the method of Chung et al. The method will result in quantitative recovery of the PEITC-NAC.</description>
        <time_frame>After 5 days of PEITC treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSTM1 Null</title>
            <description>GSTM1 Null: gene for glutathione-S-transferase (GST) M1 (GSTM1), the homozygous deletion of the gene (GSTM1 null), leading to a lack of corresponding enzymatic activity.</description>
          </group>
          <group group_id="O2">
            <title>GSTM1 Present</title>
            <description>GSTM1 Present: gene for glutathione-S-transferase (GST) M1 (GSTM1), present in one or both alleles, leading to a enzymatic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of GSTM1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</title>
          <description>Measured by high-performance liquid chromatography (HPLC). The aim is to determine the possible differential effects of GSTM1 genotype on PEITC excretion, using the method of Chung et al. The method will result in quantitative recovery of the PEITC-NAC.</description>
          <units>nmol/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEITC-NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" lower_limit="58.6" upper_limit="87.6"/>
                    <measurement group_id="O2" value="54.8" lower_limit="45.6" upper_limit="65.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ITC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="46.7" upper_limit="61.8"/>
                    <measurement group_id="O2" value="40.5" lower_limit="35.7" upper_limit="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total ITC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of GSTT1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</title>
        <description>Measured by high-performance liquid chromatography (HPLC). The aim is to determine the possible differential effects of GSTT1 genotype on PEITC excretion, using the method of Chung et al. The method will result in quantitative recovery of the PEITC-NAC.</description>
        <time_frame>After 5 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSTT1 Null</title>
            <description>GSTT1 Null: gene for glutathione-S-transferase (GST) T1 (GSTT1), the homozygous deletion of the gene (GSTT1 null), leading to a lack of corresponding enzymatic activity.</description>
          </group>
          <group group_id="O2">
            <title>GSTT1 Present</title>
            <description>GSTT1 Present: gene for glutathione-S-transferase (GST) T1 (GSTT1), present in one or both alleles, leading to a enzymatic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of GSTT1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</title>
          <description>Measured by high-performance liquid chromatography (HPLC). The aim is to determine the possible differential effects of GSTT1 genotype on PEITC excretion, using the method of Chung et al. The method will result in quantitative recovery of the PEITC-NAC.</description>
          <units>nmol/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEITC-NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" lower_limit="50.3" upper_limit="89.6"/>
                    <measurement group_id="O2" value="60.4" lower_limit="51.5" upper_limit="70.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ITC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="40.0" upper_limit="60.4"/>
                    <measurement group_id="O2" value="45.1" lower_limit="40.3" upper_limit="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Effects of GSTM1 and GSTT1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</title>
        <time_frame>After 5 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSTM1 and GSTT1 Both Genes Null</title>
            <description>GSTM1 &amp; GSTT1 Null: genes for glutathione-S-transferase (GST) M1 &amp; T1, the homozygous deletion of both genes (GSTM1 null and GSTT1 null), leading to a lack of corresponding enzymatic activity.</description>
          </group>
          <group group_id="O2">
            <title>GSTM1 and GSTT1 Only One Gene Present</title>
            <description>GSTM1 or GSTT1 Present: at least one allele positive for either the gene for glutathione-S-transferase (GST) M1 or T1, but not or both genes, leading to moderate enzymatic activity.</description>
          </group>
          <group group_id="O3">
            <title>GSTM1 and GSTT1 Both Genes Present</title>
            <description>GSTM1 and GSTT1 Present: at least one allele positive for both glutathione-S-transferase (GST) M1 and T1, leading to higher enzymatic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Effects of GSTM1 and GSTT1 Genotype on Phenethyl Isothiocyanate (PEITC)-NNK Association and on the Metabolism and Excretion of PEITC</title>
          <units>nmol/mg creatinine</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PEITC-NAC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="59.7" upper_limit="122.2"/>
                    <measurement group_id="O2" value="60.5" lower_limit="48.6" upper_limit="75.3"/>
                    <measurement group_id="O3" value="56.9" lower_limit="46.6" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total ITC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="46.3" upper_limit="76.5"/>
                    <measurement group_id="O2" value="47.1" lower_limit="40.4" upper_limit="55.0"/>
                    <measurement group_id="O3" value="41.5" lower_limit="36.1" upper_limit="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total ITC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Levels of [Pyridine-D4]Hydroxy Acid:Total [Pyridine-D4]NNAL Ratio by GSTM1 and GSTT1 Genotype.</title>
        <description>% Difference in ratio of urinary [pyridine-D4]hydroxy acid : total [pyridine-D4]NNAL while on PEITC compared to while on Placebo ((PEITC - Placebo) / PEITC) x 100%</description>
        <time_frame>After 5 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GSTM1 and GSTT1 Both Genes Null</title>
            <description>GSTM1 &amp; GSTT1 Null: genes for glutathione-S-transferase (GST) M1 &amp; T1, the homozygous deletion of both genes (GSTM1 null and GSTT1 null), leading to a lack of corresponding enzymatic activity.</description>
          </group>
          <group group_id="O2">
            <title>GSTM1 and GSTT1 Only One Gene Present</title>
            <description>GSTM1 or GSTT1 Present: at least one allele positive for either the gene for glutathione-S-transferase (GST) M1 or T1, but not or both genes, leading to moderate enzymatic activity.</description>
          </group>
          <group group_id="O3">
            <title>GSTM1 and GSTT1 Both Genes Present</title>
            <description>GSTM1 and GSTT1 Present: at least one allele positive for both glutathione-S-transferase (GST) M1 and T1, leading to higher enzymatic activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Levels of [Pyridine-D4]Hydroxy Acid:Total [Pyridine-D4]NNAL Ratio by GSTM1 and GSTT1 Genotype.</title>
          <description>% Difference in ratio of urinary [pyridine-D4]hydroxy acid : total [pyridine-D4]NNAL while on PEITC compared to while on Placebo ((PEITC - Placebo) / PEITC) x 100%</description>
          <units>percentage of change in ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.6" lower_limit="-26.7" upper_limit="-2.9"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-14.6" upper_limit="9.9"/>
                    <measurement group_id="O3" value="-9.4" lower_limit="-17.4" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Short-term Trial)</title>
          <description>Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
phenethyl isothiocyanate: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Washout</title>
          <description>9 days between treatments</description>
        </group>
        <group group_id="E3">
          <title>PEITC (Short-term Trial)</title>
          <description>Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
phenethyl isothiocyanate: Given orally
placebo: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI tract</sub_title>
                <description>Most common were dry mouth, taste alteration, stomachache, belching, flatulence, and diarrhea</description>
                <counts group_id="E1" events="103" subjects_affected="30" subjects_at_risk="107"/>
                <counts group_id="E2" events="35" subjects_affected="17" subjects_at_risk="107"/>
                <counts group_id="E3" events="284" subjects_affected="62" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="107"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="13" subjects_affected="7" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="24" subjects_affected="13" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="35" subjects_affected="17" subjects_at_risk="107"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E3" events="58" subjects_affected="25" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dorothy Hatsukami</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-2121</phone>
      <email>hatsu001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

